ARTH Insider Trading Activity and SEC Form 4 Filings
ARTH insider trading summary
No open-market insider purchases or sales of Arch Therapeutics, Inc. (ARTH) have been reported on SEC Form 4 in the past 12 months.
Latest ARTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 31, 2023 | Michael S Abrams | Chief Financial Officer | Buy | $3K (10,292 @ $0.28) |
| Aug 31, 2023 | Terrence W Norchi | President and Chief Executive | Buy | $2K (6,862 @ $0.28) |
| Aug 31, 2023 | Laurence Hicks | Director | Buy | $3K (10,292 @ $0.28) |
| May 26, 2016 | James R Sulat | Director | Buy | $0 (111,111 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.